Neurosense Therapeutics Ltd expected to post a loss of 13 cents a share - Earnings Preview

Neurosense Therapeutics

20/06/2025 12:03

Neurosense Therapeutics Ltd NRSN.OQ NRSN.O is expected to report results on June 24 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Neurosense Therapeutics Ltd is for a loss of 13 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $10.75​, above​ its last closing price of $2.45. ​​​

This summary was machine generated June 20 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)